rs8192678 — PPARGC1A Gly482Ser

Master mitochondrial biogenesis regulator — Ser482 variant reduces PGC-1alpha transcriptional activity, impairing mitochondrial production, aerobic capacity, and metabolic adaptation

See your personal result for PPARGC1A

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

PPARGC1A Gly482Ser — The Mitochondrial Biogenesis Switch

PGC-1alpha (encoded by PPARGC1A) is the master regulator of mitochondrial biogenesis — the cellular process that builds new mitochondria and determines how efficiently your cells produce energy. Every time you exercise, fast, or face cold exposure, PGC-1alpha activates a cascade that grows your mitochondrial network, shifts muscle toward oxidative (endurance-capable) fiber types, and improves insulin sensitivity. It is one of the most important proteins in aging biology, sitting upstream of pathways that govern metabolic health across decades.

The Gly482Ser variant (rs8192678, called G>A in many papers because PPARGC1A is on the minus strand of chromosome 4, but reported as C>T by 23andMe on the plus strand) substitutes serine for glycine at position 482 of the protein. This single amino acid change — in a domain critical for interaction with MEF2 transcription factors and protein stability — has consequences for aerobic capacity, diabetes risk, and the body's ability to adapt to exercise training.

The Mechanism

The Gly482 variant (C allele on the plus strand) is the higher-function form. Glycine at position 482 sits within a region of PGC-1alpha that directly interacts with myocyte enhancer factor 2 (MEF2), a key transcription factor that drives slow-twitch oxidative muscle fiber gene programs. The Steinbacher et al. study11 The Steinbacher et al. study
Steinbacher P et al. The Single Nucleotide Polymorphism Gly482Ser in the PGC-1α Gene Impairs Exercise-Induced Slow-Twitch Muscle Fibre Transformation in Humans. PLOS One, 2015 established that the Ser482 variant impairs this MEF2 binding, specifically blocking the exercise-induced conversion of fast-twitch (type II) to slow-twitch (type I) oxidative muscle fibers.

The Ser482 variant also renders the PGC-1alpha protein less stable. A CRISPR-based allele substitution study22 CRISPR-based allele substitution study
Huang M et al. Engineered allele substitution at PPARGC1A rs8192678 alters human white adipocyte differentiation, lipogenesis, and PGC-1α content and turnover. Diabetologia, 2023 using isogenic human adipocytes found that T/T (Ser482Ser) cells showed faster protein degradation, reduced PGC-1alpha protein content, and decreased transcriptional coactivator activity compared to C/C cells. This accelerated protein turnover means Ser482 carriers have less functional PGC-1alpha available to drive mitochondrial biogenesis — not because the gene is not expressed, but because the protein is degraded faster.

PGC-1alpha also regulates the NAMPT enzyme, which is rate-limiting for mitochondrial NAD+ synthesis. Reduced PGC-1alpha activity therefore impairs the mitochondrial NAD+ pool, a critical cofactor for sirtuins33 sirtuins
NAD-dependent deacetylases (SIRT1-7) that regulate mitochondrial biogenesis, DNA repair, and longevity pathways and for oxidative phosphorylation.

The Evidence

The aerobic capacity evidence is robust. In a landmark study, Lucia et al.44 Lucia et al.
Lucia A et al. PPARGC1A genotype predicts exceptional endurance capacity in European men. J Appl Physiol, 2005 genotyped 104 world-class Spanish male endurance athletes and 100 sedentary controls, finding the Ser482 allele frequency was significantly lower in elite athletes (29%) than in unfit controls (40%; P=0.01). The VO2max gap between groups was enormous (73.4 vs 29.4 mL/kg/min), confirming the Gly482 form supports superior aerobic capacity.

For type 2 diabetes, the picture is consistent across populations. A meta-analysis of 8 studies55 meta-analysis of 8 studies
Ek J et al. Meta-analysis of the Gly482Ser variant in PPARGC1A in type 2 diabetes and related phenotypes. Diabetologia, 2006 encompassing 3,718 cases and 4,818 controls found the Ser482 allele associated with modestly increased T2D risk (pooled OR 1.07-1.11). A larger 23-study meta-analysis66 23-study meta-analysis
Yang Y et al. Association of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PPARGC1A) gene polymorphisms and type 2 diabetes mellitus: a meta-analysis. Diabetes Metab Res Rev, 2011 (7,539 T2D cases, 9,562 controls) confirmed the association (OR 1.19, 95% CI 1.05-1.34), with substantially stronger effects in South Asian populations (OR 1.66, 95% CI 1.28-2.15). The Ser482 allele impairs NEFA (free fatty acid) clearance after glucose challenge, an early metabolic defect preceding overt insulin resistance.

The exercise training response is particularly revealing. In the Steinbacher et al. RCT77 Steinbacher et al. RCT
Steinbacher P et al. 2015, 28 untrained men aged 50-69 completed 10 weeks of supervised cycling (3x60 min/week). Gly/Gly men increased slow-twitch fiber proportion by 8.9% — a significant and expected adaptation. Ser allele carriers showed essentially no fiber type shift (-1.5%, NS). Mitochondrial content and capillary density improved similarly in both groups, confirming the variant specifically impairs the MEF2-dependent fiber-type adaptation program, not general mitochondrial biogenesis. This explains why Ser carriers may struggle to convert aerobic training gains into sustained endurance improvements despite similar mitochondrial volume increases.

A meta-analysis of athletic performance studies88 meta-analysis of athletic performance studies
Tharabenjasin P et al. Association of PPARGC1A Gly482Ser polymorphism with athletic performance: A meta-analysis. PLoS One, 2019 found the Gly allele significantly favored athletic performance overall (OR 1.13-1.24, p=0.001-0.002), with effects in both power (OR 1.22-1.25) and endurance sports, particularly in Caucasian populations (OR 1.19-1.29). Notably, Asian athletes showed no significant allele-based difference, suggesting gene-environment or population-specific modifiers.

Practical Implications

The Ser482 variant creates a specific metabolic vulnerability: reduced PGC-1alpha activity means the body is slower to build new mitochondria, less efficient at shifting muscle fibers toward oxidative types, and more prone to metabolic dysfunction under sedentary conditions. The two most direct intervention targets are (1) exercise type — high-intensity interval training (HIIT) activates alternative PGC-1alpha activation pathways through AMPK and p53 that may partially bypass the MEF2-binding defect, and (2) NAD+ precursors — boosting the cellular NAD+ pool supports SIRT1-mediated PGC-1alpha deacetylation and activation, compensating for the reduced protein stability of the Ser482 variant.

For Ser482 carriers, conventional aerobic training recommendations (steady-state cardio to build oxidative capacity) may underperform expectations. Incorporating HIIT and sprint-interval protocols activates calcium-dependent and AMPK-dependent PGC-1alpha activation that is less dependent on the Gly482 coactivation domain.

Interactions

PPARGC1A Gly482Ser interacts meaningfully with SOD2 rs4880 (Val16Ala). Both variants impair mitochondrial function by different mechanisms: Ser482 reduces the number and adaptation capacity of mitochondria, while Val16Ala reduces mitochondrial antioxidant (superoxide dismutase) activity. Carriers of both risk variants face a compound mitochondrial burden — fewer, less-adapted mitochondria that are also less protected from oxidative damage. This combination is a strong candidate for a compound action, as the combined recommendation (NAD+ precursors + CoQ10 + mitochondria-targeted antioxidant support) differs from either individual action alone.

FOXO3 rs2802292 is another interaction partner: FOXO3 regulates mitochondrial quality control through autophagy (mitophagy) and stress-response pathways. The longevity-protective G-allele of rs2802292 may partially compensate for reduced PGC-1alpha activity by maintaining mitophagy and clearing dysfunctional mitochondria. Conversely, Ser482 carriers who also carry the T/T (non-protective) FOXO3 genotype may face compounded age-related mitochondrial decline.

NQO1 rs1800566 (P187S) affects the recycling of CoQ10 to its active ubiquinol form — CoQ10 is a critical component of the mitochondrial electron transport chain. Carriers of both the NQO1 P187S and PPARGC1A Ser482 variants may face compounded mitochondrial energy production deficits warranting combined supplementation.

Nutrient Interactions

nicotinamide riboside increased_need
nicotinamide mononucleotide increased_need
coenzyme Q10 increased_need

Genotype Interpretations

What each possible genotype means for this variant.

CC High Mitochondrial Biogenesis Normal

Normal PGC-1alpha function with full mitochondrial biogenesis capacity

The Gly482 form of PGC-1alpha maintains the structural conformation in the RNA binding domain needed for efficient interaction with MEF2 transcription factors. This enables the full adaptive response to endurance training, including fiber-type transitions that underpin long-term aerobic capacity gains. The protein is also more stable than the Ser482 form, meaning more functional PGC-1alpha is available in cells to drive transcription of mitochondrial biogenesis genes (NRF1, TFAM, and the downstream mitochondrial genome).

Your genotype corresponds to significantly lower type 2 diabetes risk relative to Ser482 carriers and is enriched among elite endurance athletes compared to sedentary populations. The metabolic protection appears to operate through enhanced fat oxidation, better NEFA clearance, and improved insulin sensitivity, all downstream of efficient PGC-1alpha activity.

CT Intermediate Mitochondrial Function Intermediate

One reduced-function copy — moderately impaired mitochondrial adaptation

Heterozygous carriers produce both forms of PGC-1alpha protein. The net effect on mitochondrial biogenesis capacity is intermediate — studies generally find heterozygotes between the two homozygous states on aerobic performance, exercise adaptation, and metabolic risk. The fiber-type conversion response to endurance training is blunted relative to Gly/Gly individuals but not as severely impaired as in Ser/Ser homozygotes.

From a metabolic standpoint, your type 2 diabetes risk is modestly elevated relative to CC carriers. The MEF2 binding impairment from the Ser allele means that endurance training yields somewhat less efficient fast-to-slow fiber conversion, which affects long-term aerobic adaptation trajectories. Intensity matters more for this genotype: high-intensity protocols activate AMPK and p38-MAPK pathways that can drive PGC-1alpha activity independent of the MEF2 coactivation domain.

TT Reduced Mitochondrial Biogenesis Reduced

Significantly impaired PGC-1alpha function — reduced aerobic adaptation and elevated metabolic risk

The Ser/Ser genotype produces only the faster-degrading form of PGC-1alpha, resulting in lower steady-state protein levels and impaired MEF2 coactivation. The clinical consequences are measurable: in a 10-week cycling RCT, Ser allele carriers showed essentially no exercise-induced fast-to-slow muscle fiber conversion (+0% vs +8.9% in Gly/Gly men), despite comparable mitochondrial volume and capillary density increases. This fiber-type adaptation impairment is the key deficit: slow-twitch oxidative fibers are more insulin-sensitive and more fatigue-resistant, so their absence elevates long-term metabolic and aerobic capacity risk.

The metabolic consequences compound over time. Elite endurance athletes are significantly depleted of the Ser allele (29% in world-class athletes vs 40% in sedentary controls), reflecting the cumulative advantage of the Gly482 form across years of training adaptation. For Ser/Ser carriers, aerobic training will still improve fitness, but the trajectory favors intensity-focused protocols that activate non-MEF2 PGC-1alpha pathways.

The CRISPR allele substitution study confirmed that T/T adipocytes have lower PGC-1alpha protein content, faster protein degradation, and reduced coactivator activity. Free fatty acid clearance is also blunted in Ser482 carriers following glucose challenge — an early metabolic defect that precedes overt insulin resistance.